Epidemiology of Morbidity and Mortality of COVID-19 Patients During the Period of June 2020-September 2021 in Sulianti Saroso Infectious Disease Hospital, Indonesia.

IF 1.1 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Malaysian Journal of Medical Sciences Pub Date : 2024-10-01 Epub Date: 2024-10-08 DOI:10.21315/mjms2024.31.5.15
Pompini Agustina Sitompul, Nina Mariana, Siti Maemun, Aninda Dinar Widiantari, Farida Murtiani, Rosamarlina Rosamarlina, Adria Rusli, Titi Sundari, Tri Bayu Purnama
{"title":"Epidemiology of Morbidity and Mortality of COVID-19 Patients During the Period of June 2020-September 2021 in Sulianti Saroso Infectious Disease Hospital, Indonesia.","authors":"Pompini Agustina Sitompul, Nina Mariana, Siti Maemun, Aninda Dinar Widiantari, Farida Murtiani, Rosamarlina Rosamarlina, Adria Rusli, Titi Sundari, Tri Bayu Purnama","doi":"10.21315/mjms2024.31.5.15","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The increasing mortality rate of COVID-19 has remained an international public health concern. Limited studies on clinical treatment and morbidity in hospital settings are available in Indonesia. This present study aims to analyse demographic characteristics, clinical signs and treatment in COVID-19 patients and their association to the mortality case in Sulianti Saroso Infectious Disease Hospital.</p><p><strong>Methods: </strong>The study applied a retrospective cohort approach to all COVID-19 inpatients confirmed by polymerase chain reaction (PCR) testing in Sulianti Saroso Infectious Disease Hospital from 1 June 2020 to 30 September 2021. Overall survival rates until the end of the study were calculated using the Kaplan-Meier method and compared using the log-rank test. A Cox regression model was used to evaluate the crude and adjusted hazard ratios for associated factors.</p><p><strong>Results: </strong>We collected 1,970 inpatient data that met our inclusion and exclusion criteria. Most of them were 19 years old-59 years old (73.2%) and male (52.6%), and 966 (49%) patients had comorbidities. Approximately 63.9%, 89.2%, 89.8%, 82%, and 14.1% of the patients had ferritin levels ≤ 800, received antiviral treatment, were treated in non-intensive wards, had a moderate or mild clinical stage and did not survive, respectively. In the adjusted analysis, mortality was associated with sex (hazard ratio [HR]: 1.12; 95% CI: 1.02, 1.23), presence of comorbidity (HR: 1.19; 95% CI: 1.08, 1.30) and favipiravir (FPV) plus azithromycin treatment (HR: 1.21; 95% CI: 1.06,1.39). FPV treatment (HR: 1.35; 95% CI: 1.04, 1.75) was associated with higher mortality.</p><p><strong>Conclusion: </strong>Tailored approaches to treatment, considering individual risk factors and comorbidities, are crucial in improving patient outcomes.</p>","PeriodicalId":47388,"journal":{"name":"Malaysian Journal of Medical Sciences","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11477462/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Malaysian Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21315/mjms2024.31.5.15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/8 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: The increasing mortality rate of COVID-19 has remained an international public health concern. Limited studies on clinical treatment and morbidity in hospital settings are available in Indonesia. This present study aims to analyse demographic characteristics, clinical signs and treatment in COVID-19 patients and their association to the mortality case in Sulianti Saroso Infectious Disease Hospital.

Methods: The study applied a retrospective cohort approach to all COVID-19 inpatients confirmed by polymerase chain reaction (PCR) testing in Sulianti Saroso Infectious Disease Hospital from 1 June 2020 to 30 September 2021. Overall survival rates until the end of the study were calculated using the Kaplan-Meier method and compared using the log-rank test. A Cox regression model was used to evaluate the crude and adjusted hazard ratios for associated factors.

Results: We collected 1,970 inpatient data that met our inclusion and exclusion criteria. Most of them were 19 years old-59 years old (73.2%) and male (52.6%), and 966 (49%) patients had comorbidities. Approximately 63.9%, 89.2%, 89.8%, 82%, and 14.1% of the patients had ferritin levels ≤ 800, received antiviral treatment, were treated in non-intensive wards, had a moderate or mild clinical stage and did not survive, respectively. In the adjusted analysis, mortality was associated with sex (hazard ratio [HR]: 1.12; 95% CI: 1.02, 1.23), presence of comorbidity (HR: 1.19; 95% CI: 1.08, 1.30) and favipiravir (FPV) plus azithromycin treatment (HR: 1.21; 95% CI: 1.06,1.39). FPV treatment (HR: 1.35; 95% CI: 1.04, 1.75) was associated with higher mortality.

Conclusion: Tailored approaches to treatment, considering individual risk factors and comorbidities, are crucial in improving patient outcomes.

印度尼西亚 Sulianti Saroso 传染病医院 2020 年 6 月至 2021 年 9 月期间 COVID-19 患者发病率和死亡率的流行病学。
目的:COVID-19 死亡率的上升一直是国际公共卫生关注的问题。在印度尼西亚,有关医院临床治疗和发病率的研究十分有限。本研究旨在分析Sulianti Saroso传染病医院COVID-19患者的人口统计学特征、临床症状和治疗方法,以及它们与死亡病例的关系:该研究采用回顾性队列方法,对 2020 年 6 月 1 日至 2021 年 9 月 30 日期间在 Sulianti Saroso 传染病医院通过聚合酶链反应(PCR)检测确诊的所有 COVID-19 住院患者进行研究。研究结束前的总生存率采用 Kaplan-Meier 法计算,并采用 log-rank 检验进行比较。采用 Cox 回归模型评估相关因素的粗略危险比和调整危险比:我们收集了1970名符合纳入和排除标准的住院患者数据。其中大多数患者年龄在 19 岁至 59 岁之间(73.2%),男性(52.6%),966 名患者(49%)患有合并症。分别约有 63.9%、89.2%、89.8%、82% 和 14.1%的患者铁蛋白水平≤800、接受过抗病毒治疗、在非重症病房接受治疗、临床分期为中度或轻度以及未能存活。在调整后的分析中,死亡率与性别(危险比[HR]:1.12;95% CI:1.02,1.23)、是否存在合并症(HR:1.19;95% CI:1.08,1.30)和法非拉韦(FPV)加阿奇霉素治疗(HR:1.21;95% CI:1.06,1.39)有关。FPV治疗(HR:1.35;95% CI:1.04,1.75)与较高的死亡率相关:结论:考虑个体风险因素和合并症的定制化治疗方法对改善患者预后至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Malaysian Journal of Medical Sciences
Malaysian Journal of Medical Sciences MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
2.70
自引率
0.00%
发文量
89
审稿时长
9 weeks
期刊介绍: The Malaysian Journal of Medical Sciences (MJMS) is a peer-reviewed, open-access, fully online journal that is published at least six times a year. The journal’s scope encompasses all aspects of medical sciences including biomedical, allied health, clinical and social sciences. We accept high quality papers from basic to translational research especially from low & middle income countries, as classified by the United Nations & World Bank (https://datahelpdesk.worldbank.org/knowledgebase/ articles/906519), with the aim that published research will benefit back the bottom billion population from these countries. Manuscripts submitted from developed or high income countries to MJMS must contain data and information that will benefit the socio-health and bio-medical sciences of these low and middle income countries. The MJMS editorial board consists of internationally regarded clinicians and scientists from low and middle income countries.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信